Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer

This publication has 43 references indexed in Scilit:

• A Robust Method for Estimating Optimal Treatment Regimes
  Biometrics, 2012
• Analysis of randomized comparative clinical trial data for personalized treatment selections
  Biostatistics, 2010
• A Generalized Estimator of the Attributable Benefit of an Optimal Treatment Regime
  Biometrics, 2010
• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
  The Lancet Oncology, 2010
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
  The Lancet, 2009
• A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment
  JNCI: Journal of the National Cancer Institute, 2009
• Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
  JNCI: Journal of the National Cancer Institute, 2009
• Lost in translation: Problems and pitfalls in translating laboratory observations to clinical utility
  European Journal of Cancer, 2008
• Development and validation of biomarker classifiers for treatment selection
  Journal of Statistical Planning and Inference, 2007
• A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
  New England Journal of Medicine, 2004